DCDC Tx: Drug-Companion Diagnostic Company

Therapy development

A powerhouse for precision therapy development for any disease, based on unique mechanistic insight

Mission Statement

Our mission: development of precision treatment for a wide variety of serious and invalidating diseases lacking adequate treatment, including children’s diseases, with focus on high therapy effectivity and quality of life for the individual patient.

Why DCDC Tx?

DCDC-Tx has proven that its proprietary STAP-STP technology can be applied to identify clinically effective drugs, e.g. in inflammatory bowel disease, breast cancer, and viral disease.

Many drugs fail in (expensive) late stage clinical studies: while the drug works in cells and mice in the laboratory (laboratory disease models), it may not work adequately in patients. Or at best in a subgroup of patients who cannot be properly identified.

Important reasons are: (1) lack of insight in human disease pathophysiology (the ‘mechanism of disease‘) and its variations; (2) insufficient or incorrect knowledge on the mechanism of action of drugs; (3) patients differ from laboratory disease models: laboratory disease models are often not sufficiently similar to patients.

DCDC Tx provides the solution to this problem using its proprietary STAP-STP technology to quantify activity of all 20 STP’s that together determine healthy or diseased cell function. This provides crucial new insights with respect to the ‘mechanism of disease’ at the level of the individual patient and the ‘mechanism of action‘ of drugs; enables uses human laboratory disease models which are directly and quantitatively comparable to patients, and identifies the patient subgroup who responds to the therapy.


DCDC-Tx focusses on preclinical drug development and patents new therapies, primarily based on a “drug repurposing” strategy. Around 25,000 drugs have been FDA-approved and can be used. DCDC Tx has obtained a license for drug/therapy development on first-of-kind Signal Transduction Pathway (STAP-STP)-technology, developed during the past 14 years at Philips Research by members of the DCDC Tx team.

STAP-STP technology enables characterization of the ‘mechanism of disease’ in patient samples and disease models, as basis for drug development, and is also used to develop a test to select the patients who will respond to the developed therapy.

DCDC Tx enables development of personalized treatments.

Latest news